Myopia Profile Sign in Sign in

Knowledge Centre.

Featured
ARVO2025 Recap #1 - Updates in myopia control spectacles Spectacles

ARVO2025 Recap #1 - Updates in myopia control spectacles

This first recap brings you updates on DIMS, CARE, HALT, and other lens technologies from ARVO 2025.

Popular
The next generation spectacle lenses for myopia controlMyopia control efficacyThe next generation spectacle lenses for myopia control
Understanding the new Essilor® Stellest® spectacle lensMyopia control efficacyUnderstanding the new Essilor® Stellest® spectacle lens
How much axial length growth is normal?Axial lengthHow much axial length growth is normal?

All Types
Featured
ARVO2025 Recap #1 - Updates in myopia control spectaclesSpectaclesARVO2025 Recap #1 - Updates in myopia control spectaclesThis first recap brings you updates on DIMS, CARE, HALT, and other lens technologies from ARVO 2025.
Popular
The next generation spectacle lenses for myopia controlMyopia control efficacyThe next generation spectacle lenses for myopia controlThe newest myopia controlling spectacles can both correct and control myopia as well as contact lens options. Here we investigate.
Popular
Understanding the new Essilor® Stellest® spectacle lensMyopia control efficacyUnderstanding the new Essilor® Stellest® spectacle lensSpectacle lenses which effectively control myopia progression are the next phase in widespread myopia management. Learn more about the Essilor® Stellest® lens.
Popular
How much axial length growth is normal?Axial lengthHow much axial length growth is normal?How much axial length growth is normal? What about a myope vs an emmetrope? Can you use this to see if your myopia control is working?Novel multiregion spectacle lenses versus HAL for myopia controlAxial lengthNovel multiregion spectacle lenses versus HAL for myopia controlOne-year trial comparing Grid Dimension Multiregion (GDM) and HAL myopia control spectacles shows borderline axial length benefit and reduced efficacy over time.Back to ortho-k basics: from hesitation to confident recommendationOrtho-kBack to ortho-k basics: from hesitation to confident recommendationThis article provides a practical approach to ortho-k, from treatment selection to patient communication.Inside the Consultation Room – Q&A on mEYE® Suite with Amit SharmaClinical communicationInside the Consultation Room – Q&A on mEYE® Suite with Amit SharmaAmit Sharma discusses using Ocumetra’s mEYE® Suite in practice.DIMS plus atropine vs ortho-k for myopia controlAxial lengthDIMS plus atropine vs ortho-k for myopia controlA one-year real-world study found DIMS spectacles with 0.01% atropine produced marginally less axial elongation than ortho-k in children with myopia.Early-onset high myopia and underlying diseaseCauses of myopiaHigh myopiaEarly-onset high myopia and underlying diseaseEarly-onset high myopia is linked to ocular and systemic disease in 60% of cases, highlighting the need for targeted clinical workup.Retinal re-detachment after cataract surgery in myopic eyesHigh myopiaMechanismsRetinal re-detachment after cataract surgery in myopic eyesCataract surgery after retinal detachment repair shows similar re-detachment risk across myopia levels, with higher risk observed in younger patientsAssessing the value of prior myopia progression dataAxial lengthAssessing the value of prior myopia progression dataPrior 12-month changes in SER and AL were found not to be reliable indicators of future myopia progression in children aged 5 to 12 years.Four key insights from the seven-year MiSight® 1 day studyClinical communicationFour key insights from the seven-year MiSight® 1 day studyRead about key insights from participants in the 7-year MiSight study. ASPECT trial finds 0.025% atropine and DIMS lenses slow axial lengthAxial lengthASPECT trial finds 0.025% atropine and DIMS lenses slow axial length This randomised controlled trial found that 0.025% atropine with DIMS lenses slowed axial length growth more than 0.025% atropine with standard spectacles

Enormous thanks to our visionary sponsors

Myopia Profile’s growth into a world leading platform has been made possible through the support of our visionary sponsors, who share our mission to improve children’s vision care worldwide. Click on their logos to learn about how these companies are innovating and developing resources with us to support you in managing your patients with myopia.